...We Welcome You To The Resverlogix HUB In The AGORACOM COMMUNITY!

** Apabetalone (RVX-208) Currently Being Tested in a Phase 3 BETonMACE Cardiovascular Outcomes Trial ** BETonMACE Trial is Fully Enrolled and Expected to be Completed H1 2019 https://clinicaltrials.gov/ct2/show/NCT02586155

Message: Abstract - first example of a "curative" effect?

Interesting for sure

The resistance to BETi’s appears to be linked to increased NfKb which when inhibited restores sensitivity to BETi’s

check out latest PubMed abstract on Brd4, which wasnt JQ1


New Message
Please login to post a reply